跳至主要内容
临床试验/JPRN-UMIN000016998
JPRN-UMIN000016998招募中未知

Effect of Tolvaptan on polycystic liver and kidney is autosomal dominant polycystic kidney disease - GLSG ADPKD

Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine0 个研究点目标入组 5 人开始时间: 2020年1月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. The patient having a history of allergy to Tolvaptan or its analog. 2. The patient cannot feel thirsty or is unable to consume liquid. 3. The patient with hypernatremia. 4. The patient with severe renal function (less than eGFR 15mL/min/1.73m2). 5. The patient with chronic hepatitis or drug-induced liver injury of the history of these disease (except liver cysts). 6. The pregnant woman or the woman who has the possibility of the pregnancy. 7. The patient whom the primary doctor think not appropriate for participating the trial.

研究者

发起方
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine

相似试验